Biacetyl monoxime

Biacetyl monoxime (Diacetyl monoxime), a myosin ATPase inhibitor, is a skeletal and cardiac muscle contraction inhibitor. Biacetyl monoxime is also a well-characterized non-competitive inhibitor of chemical and motile activity of skeletal muscle myosin-II. Biacetyl monoxime induces sarcoplasmic reticulum Ca²⁺ release^[1][2][3]. In Vitro: Biacetyl monoxime (Diacetyl monoxime) (50 mM, 6 and 48 h) decreases cellulase secretion in C. cinerea^[1].
Biacetyl monoxime (50 mM, 2 and 4 h) disrupts the localization of the Golgi apparatus, but not that of the endoplasmic reticulum^[1].
Biacetyl monoxime (0-30 mM) induces SR Ca²⁺ release (no efflux inhibitors) in a concentration-dependent manner, with a maximal reduction of 72% of SR Ca²⁺ at pCa 6.0^[2].
Biacetyl monoxime acts as a chemical phosphatase, which has led to speculation that dephosphorylation of key Ca²⁺ channel proteins may be involved in its inhibition of contraction^[2].
Biacetyl monoxime does not inhibit the ATPase activity of two different myosin-I isoforms, myosin-V, or myosin-VI^[3].
Biacetyl monoxime (0-50 mM) suppresses L-type Ca²⁺ current of single cardiac myocytes isolated from SHR and WKY rats^[4].
Biacetyl monoxime significantly reduces the duration of both spontaneous and electrically stimulated action potentials of cultured neonatal rat cardiomyocytes^[4]. In Vivo: Biacetyl monoxime (0-200 mg/kg; i.v.; once) shows hypotensive effect^[4].
Biacetyl monoxime (0-205 mg/kg; i.p.; once) shows anticonvulsant effect against Picrotoxin (HY-101391)-induced convulsions^[5].